Literature DB >> 10925423

Modified Z-epicanthoplasty in the Asian eyelid.

J I Park.   

Abstract

OBJECTIVE: To propose a new technique for eliminating the medial epicanthal fold of the Asian upper eyelid.
DESIGN: A retrospective review of the Z-epicanthoplasty and modified Z-epicanthoplasty procedures performed during 1995 through 1999.
SETTING: Facial plastic surgery private practice. PATIENTS: Four hundred seventy-five Korean American patients from 9 midwestern states with type 2 or type 3 medial epicanthal folds.
CONCLUSIONS: The majority of the East Asian population has type 2 or 3 medial epicanthal folds. Most surgeons avoid epicanthoplasty because of the fear of visible scar formation. Modified Z-epicanthoplasty is a safe and effective technique for eliminating the epicanthal fold during double-eyelid operations. Scarring of the medial canthal area has not been a problem with this technique. Arch Facial Plast Surg. 2000;2:43-47

Entities:  

Mesh:

Year:  2000        PMID: 10925423     DOI: 10.1001/archfaci.2.1.43

Source DB:  PubMed          Journal:  Arch Facial Plast Surg        ISSN: 1521-2491


  4 in total

1.  Asian blepharoplasty.

Authors:  Marilyn Q Nguyen; Patrick W Hsu; Tue A Dinh
Journal:  Semin Plast Surg       Date:  2009-08       Impact factor: 2.314

2.  Skin redraping for correction of lower eyelid epiblepharon combined with medial epicanthal fold: a retrospective analysis of 286 Asian children.

Authors:  Ninghua Liu; Aijuan He; Lan Gong; Nan Song; Dan Wu
Journal:  Eye (Lond)       Date:  2021-04-29       Impact factor: 3.775

3.  Restoration of Complicated Epicanthus: Modified Reverse Skin Redraping With Mini-epicanthoplasty for Rescue in Unsatisfied Epicanthoplasty Patients.

Authors:  Yoon Jae Chung; Kyung Eun Han; Bo Young Park
Journal:  Ann Plast Surg       Date:  2017-06       Impact factor: 1.539

4.  Relationship between lower eyelid epiblepharon and epicanthus in Korean children.

Authors:  Dong Hoon Shin; Kyung In Woo; Yoon-Duck Kim
Journal:  PLoS One       Date:  2017-11-21       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.